Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Biotech -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (38)	9/3/2002 2:23:01 PM
From: nigel bates	Read Replies (1) \| Respond to of 70

NWBT - hadn't noticed that; thanks. July 29 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (Nasdaq: NWBT - News) today announced that it has retained C.E. Unterberg, Towbin, an investment bank, to assist in searching out strategic alternatives, including the sale or merger of the company or any of its development programs. C.E. Unterberg, Towbin was the managing underwriter of the Company's December 2001 initial public offering. "We are confident that this investment bank will bring us opportunities that will reflect the true value of our various technological assets. Our essential business activities continue to move forward," stated Daniel O. Wilds, President and Chief Executive Officer... As of June 30, 2002, Northwest Biotherapeutics had approximately $7.4 million in unrestricted cash and cash equivalents. The Company intends to manage its operating cash requirements so that its current cash balance will be sufficient to fund its operations through the end of 2002... The Company's lead DCVax product candidate, DCVax-Prostate, is a prostate cancer treatment that is in a Phase III clinical trial. Northwest Biotherapeutics is initiating a multi-site Phase II clinical trial to evaluate DCVax-Brain as a possible treatment for Glioblastoma Multiforme, a lethal form of brain cancer as well as a Phase I trial evaluation of its DCVax-Lung as a potential treatment for lung cancer. HuRx is a human monoclonal antibody program that is being co-developed with Medarex, Inc. Northwest Biotherapeutics' lead HuRx product candidate, HuRx-Prostate is currently being manufactured for anticipated Phase I clinical trials...